Cadila Healthcare’s wholly owned subsidiary -- Zydus Pharmaceuticals (USA) has received final approval from the United States Food & Drug Administration (USFDA) to market Valacyclovir Tablets USP in strengths of 500 mg and 1 gm. The drug is indicated for the treatment of cold sores (herpes labialis), genital herpes, chickenpox and herpes zoster (shingles). It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.
The group now has more than 180 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1672.45 |
| Dr. Reddys Lab | 1223.60 |
| Cipla | 1230.40 |
| Zydus Lifesciences | 929.00 |
| Lupin | 2331.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: